SCHEMBL1822907

SCHEMBL1822907

CS(=O)(=O)Oc1cccc(C(CNC(=O)OCc2ccccc2)C(=O)OCc2ccccc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 7/20 0.43
CA2 P00918 6/20 0.43
ACHE P22303 4/20 0.43
SYK P43405 1/20 0.42
CA12 O43570 2/20 0.42
CA9 Q16790 2/20 0.42
CTSS P25774 3/20 0.41
CTSL P07711 2/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
FAAH O00519 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ADRB2 P07550 1/20 0.40
ADRB3 P13945 1/20 0.40
CTSB P07858 1/20 0.40
CTSK P43235 1/20 0.40
PPARG P37231 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1829064 0.95 HSD17B10 (0.47) CA1CA2ACHESYKCA12
SCHEMBL1821259 0.95 CA1 (0.44) CA1CA2ACHESYKCA12
SCHEMBL3578145 0.92 CA1 (0.42) CA1CA2ACHECTSSCTSL
SCHEMBL1823944 0.92 MTNR1A (0.50) CA1CA2ACHELMNASMN1; SMN2
SCHEMBL1824565 0.91 SYK (0.50) CA1CA2ACHESYKCA12
SCHEMBL1826404 0.91 SYK (0.53) CA1CA2ACHESYKCA12
SCHEMBL1823736 0.88 CA1 (0.42) CA1CA2ACHECA12CA9
SCHEMBL3576934 0.88 CASP3 (0.42)
SCHEMBL1829258 0.88 CA1 (0.50) CA1CA2ACHESYKCA12
SCHEMBL1825362 0.87 BCHE (0.45) CA1CA2ACHEFAAHADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2161254-B1 Intermediate for preparing a biaryl compound SUMITOMO CHEMICAL CO (JP) 2014-08-13 EP disclosed
EP-1481967-B1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2011-05-04 EP disclosed
US-7714157-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
EP-2161254-A1 Intermediate for preparing a biaryl compound Sumitomo Chemical Company, Limited (JP) 2010-03-10 EP disclosed
US-20070270603-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-11-22 US disclosed
US-7271280-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-18 US disclosed
EP-1481967-A1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2004-12-01 EP disclosed
US-20040158093-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158093-A1 Process for preparing a biaryl compound CYP1B1, REL, CYP2F1 CA1 1603/4885CA2 730/4885ACHE 3905/4885
US-20070270603-A1 Process for preparing a biaryl compound CYP4A11, CYP4B1, CYP51A1 CA1 1728/4885CA2 349/4885ACHE 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.